U.s. NeuroSurgical(OTC) USNU

U.S. NeuroSurgical Holdings, Inc. specializes in operating facilities for stereotactic radiosurgery, utilizing advanced gamma knife technology. This innovative approach effectively treats brain tumors and cerebral malformations, positioning the company as a key player in the healthcare sector.

Products and Services

• Gamma knife technology for non-invasive brain surgery
• Specialized facilities for advanced neurosurgical procedures
• Comprehensive patient care and support services

Growth Outlook

• Increasing demand for non-invasive surgical options in neurosurgery
• Expansion plans to enhance facility capabilities and reach
• Potential partnerships with healthcare providers to broaden service offerings

Financial Highlights

• Q2 2026 revenue of $1.31 million, showing a steady demand for services
• Cash and cash equivalents of $1.3 million as of June 30, 2026
• Trailing twelve months (TTM) gross profit margin of 10.8%

U.S. NeuroSurgical Holdings, Inc. has established itself in the healthcare industry by focusing on innovative surgical solutions. The company's gamma knife technology offers a non-invasive alternative for patients, which is increasingly sought after in modern medicine. The growth outlook remains positive, driven by rising demand for advanced neurosurgical procedures and potential collaborations with other healthcare entities. Financially, the company reported a revenue of $1.31 million in the second quarter of 2026, indicating a consistent demand for its services. The cash position of $1.3 million provides a solid foundation for future operations and potential expansions. The gross profit margin of 10.8% over the trailing twelve months reflects the company's ability to manage costs effectively while delivering specialized services. Overall, U.S. NeuroSurgical Holdings, Inc. presents an intriguing opportunity for investors interested in the healthcare sector, particularly in innovative surgical technologies.